Boule Diagnostics: Component access lifts gross margin - ABG

Gross margin at 46.2% due to improved market situation
New 5-part instrument for veterinary use launch in Q2'23
Conference call at 10:00 CET


Q1 results

Net sales came at SEK 143.1 (-1% vs. ABGSCe 144m). Adj. EBIT of SEK 14.1m, -11% below ABGSCe at 15.9m. The adjustments account for non-recurring costs of SEK 2m for the staff reductions carried out in January. Organic growth was -2.7% compared to ABGSCe at -1%. The gross margin was 46.2%, above ABGSCe at 44%, due to the supply of electronic components and other inputs improving during the quarter and the additional costs seen during 2022 resulting from relying on the spot market have gone down (no new purchases on spot market made during the quarter). Net profit was SEK 7.9m (-26%% vs. ABGSCe at 10.6m). Boule delivered 1,039 instruments, above of ABGSCe of 830. Africa/Middle East sales stand out with a strong 91% growth y-o-y, while the Eastern Europe region was on the weak side with a 47% decline.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/boule-diagnostics/Equity-research/2023/5/boule-diagnostics---component-access-lifts-gross-margin/